Skip to main content
Caplight Logo









CytoImmune Therapeutics

CytoImmune Therapeutics

Private
Duarte, CaliforniaHealthcare & Life Scienceshttps://www.cytoimmune.com/

Last Round

Series A

Aug 6, 2021

Total Funding Raised

$36M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

CytoImmune Therapeutics is a clinical-stage biotechnology company that develops engineered natural killer (NK) cell-based cancer immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyallogeneic cell therapyoff-the-shelf cell therapycontract development and manufacturing organizationCDMOcell therapy manufacturingCAR-NKbiopharmaceutical manufacturingclinical-stage biotechoncology therapeuticsimmunotherapyGMP manufacturingbiotech services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CytoImmune Therapeutics Comparables

Compare CytoImmune Therapeutics with similar companies based on industry and business-model similarity.

CytoImmune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ONK Therapeutics
87%
Shoreline Biosciences
86%
Artiva
78%

CytoImmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 6, 2021

Key People

Founding team and executive leadership

Jose Eduardo Vidal

Chief Executive Officer

Executive Team

CytoImmune Therapeutics Investors

Notable investors and investment history

CytoImmune Therapeutics investors
InvestorRounds
Sofinnova PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 89% MoM.

  • Apr 4, 2026

    Monthly visitors increased 832% MoM.

CytoImmune Therapeutics Filings

Explore SEC and related filing metadata, where available.

CytoImmune Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CytoImmune Therapeutics's valuation, stock price, and market status.

Is CytoImmune Therapeutics a public or private company?

CytoImmune Therapeutics is a private company.

What is the current stock price of CytoImmune Therapeutics?

CytoImmune Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is CytoImmune Therapeutics worth (valuation)?

Valuation information for CytoImmune Therapeutics is not publicly available.

Can I buy CytoImmune Therapeutics stock?

CytoImmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CytoImmune Therapeutics's last funding round?

CytoImmune Therapeutics's most recent funding round was Series A on August 6, 2021.

Who are the main investors in CytoImmune Therapeutics?

Key investors in CytoImmune Therapeutics include Sofinnova Partners.

Will CytoImmune Therapeutics IPO soon?

No public IPO plans have been announced for CytoImmune Therapeutics.

How can I track CytoImmune Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CytoImmune Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDuarte, California
Employee Range14
Year Founded2017
Last FundingAug 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?